Program
LM-168
A development code.
In Sino Biopharmaceutical's pipeline, CTLA-4TME单抗
. Its studies are led by Sino Biopharmaceutical.
Furthest: phase 2, since Feb 6, 20252 company-led studies, 2 open or runningNext primary completion: Aug 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 22 open or running | phase 2since Feb 6, 2025 | Feb 6, 2025 | Aug 1, 2027phase 2 · NCT06868199 |
- Named in Sino Biopharmaceutical’s own pipeline as
LM-168
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2025First study: phase 2 study in Advanced Solid TumoursFirst studyNCT06868199 · 87 planned · Australia, China
- Jun 10, 2026Phase 2 study in Advanced Solid TumorNCT07669415 · 108 planned · China
Ahead
- Aug 1, 2027Primary completion: phase 2 study in Advanced Solid TumoursNCT06868199
- Dec 15, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT07669415
TargetBeta
“CTLA-4TME单抗”the company's pipeline, read by Claude · source
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07669415Advanced Solid Tumor · China | 2 | Recruiting | Dec 15, 2027 | 108 |
| NCT06868199Advanced Solid Tumours · Australia, China | 2 | Recruiting | Aug 1, 2027 | 87 |
How it is read
Names in the registry
- “LM-168”, 2 entries
Codes read as this program: LM168.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.